Director Dealing
Updated : 07:00
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company")
Director Dealing
Alderley Park, 8 November 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces the following dealings in the Company's ordinary shares of 1 pence each ("Ordinary Shares").
Professor Robert Hawkins, a Non‐Executive Director of the Company, has purchased 100,000 Ordinary Shares via four transactions which are summarised in the table below:
Date of transaction | Number of Ordinary Shares purchased | Price per Ordinary Share |
2 November 2021 | 35,000 | 21.9p |
3 November 2021 | 15,000 | 23p |
3 November 2021 | 30,000 | 24.625p |
4 November 2021 | 20,000 | 22.44p |
Following these transactions, Professor Hawkins is beneficially interested in 225,000 Ordinary Shares, representing 0.34% of the Company's total issued share capital.
**Ends**
For more information, please contact:
|
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.
The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.
BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Robert Hawkins | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Non-Executive Director | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | BiVictriX Therapeutics plc | ||||
b) | LEI | 213800ZI85IZNA6N3L53 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of 1 pence each GB00BNXH3K91 | ||||
Identification code | ||||||
b) | Nature of the transactions | Purchase of 100,000 Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: - Aggregated volume - Price |
| ||||
e) | Date of the transactions | 2 - 4 November 2021 | ||||
f) | Place of the transactions | AIM, London Stock Exchange |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.